Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Cholesterol Test (Lipid Disorder Screening)

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44341   clinical trials with a EudraCT protocol, of which   7370   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    54 result(s) found for: Cholesterol Test (Lipid Disorder Screening). Displaying page 1 of 3.
    1  2  3  Next»
    EudraCT Number: 2006-005747-29 Sponsor Protocol Number: BP20843 Start Date*: 2007-03-14
    Sponsor Name:F. HOFFMANN-LA ROCHE LTD
    Full Title: Evaluation of the relationship between HDL quantity and HDL functionality in patients treated with HDL-C raising drugs
    Medical condition: Primary hypercholesterolemia or mixed dyslipidemia
    Disease: Version SOC Term Classification Code Term Level
    9.1 10020604 Hypercholesterolemia LLT
    9.1 10058110 Dyslipidemia LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed) IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2020-002630-32 Sponsor Protocol Number: NN6435-4697 Start Date*: 2021-07-27
    Sponsor Name:Novo Nordisk A/S
    Full Title: Dose response and safety of an oral PCSK9i, NNC0385-0434, in patients with established atherosclerotic cardiovascular disease (ASCVD) or ASCVD risk on maximally tolerated statin dose and other lipi...
    Medical condition: Established atherosclerotic cardiovascular disease (ASCVD) or ASCVD risk Elevated cholesterol
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004866 10051615 Atherosclerotic cardiovascular disease LLT
    20.1 10022891 - Investigations 10005425 Blood cholesterol increased PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) GR (Completed) NL (Completed) BE (Completed) PL (Completed)
    Trial results: View results
    EudraCT Number: 2007-000582-37 Sponsor Protocol Number: CHOL00107 Start Date*: 2007-09-21
    Sponsor Name:Genzyme Europe BV
    Full Title: A Phase 4 Randomised, Double-Blind, Placebo-Controlled, Parallel-Group, Multi-Centre Study of Colesevelam as Add-on Therapy in Patients with Familial Hypercholesterolaemia
    Medical condition: Familial hypercholesterolaemia
    Disease: Version SOC Term Classification Code Term Level
    9.1 10049593 Familial hypercholesterolaemia LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Completed) FR (Completed) DE (Completed) GB (Completed)
    Trial results: View results
    EudraCT Number: 2021-005065-40 Sponsor Protocol Number: TA-8995-302 Start Date*: 2022-05-13
    Sponsor Name:NewAmsterdam Pharma B.V.
    Full Title: Obicetrapib on Top of Maximum Tolerated Lipid-Modifying Therapies (BROADWAY): A Placebo-Controlled, Double-Blind, Randomized Phase 3 Study to Evaluate the Effect of 10 mg Obicetrapib in Participant...
    Medical condition: dyslipidemia heterozygous familial hypercholesterolemia (HeFH) atherosclerotic cardiovascular disease (ASCVD)
    Disease: Version SOC Term Classification Code Term Level
    20.1 100000004848 10020049 High cholesterol LLT
    20.0 100000004850 10057079 Heterozygous familial hypercholesterolemia LLT
    26.0 100000004866 10051615 Atherosclerotic cardiovascular disease LLT
    20.0 100000004866 10076622 Atherosclerotic plaque LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Completed) DK (Completed) CZ (Completed)
    Trial results: (No results available)
    EudraCT Number: 2014-004856-68 Sponsor Protocol Number: CB8025-21427 Start Date*: 2015-04-29
    Sponsor Name:CymaBay Therapeutics, Inc.
    Full Title: A 12-week, open-label, dose-escalating, phase 2 study to evaluate the effects of MBX-8025 in patients with Homozygous Familial Hypercholesterolemia (HoFH)
    Medical condition: Homozygous Familial Hypercholesterolemia
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NO (Completed) NL (Completed) FR (Completed)
    Trial results: View results
    EudraCT Number: 2017-002472-30 Sponsor Protocol Number: MDCO-PCS-17-03 Start Date*: 2018-01-04
    Sponsor Name:The Medicines Company
    Full Title: A PLACEBO-CONTROLLED, DOUBLE-BLIND, RANDOMIZED TRIAL TO EVALUATE THE EFFECT OF 300 MG OF INCLISIRAN SODIUM GIVEN AS SUBCUTANEOUS INJECTIONS IN SUBJECTS WITH HETEROZYGOUS FAMILIAL HYPERCHOLESTEROLEM...
    Medical condition: Hypercholesterolemia
    Disease: Version SOC Term Classification Code Term Level
    20.1 100000004861 10020604 Hypercholesterolemia LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed) ES (Completed) CZ (Completed) SE (Completed) DK (Completed)
    Trial results: View results
    EudraCT Number: 2020-004393-22 Sponsor Protocol Number: LIB003-006 Start Date*: 2022-01-13
    Sponsor Name:LIB Therapeutics, LLC
    Full Title: Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study to Evaluate the Long-Term Efficacy and Safety of LIB003 in Patients With Cardiovascular Disease, or at High Risk for Cardiovascular Disea...
    Medical condition: Patients With Cardiovascular Disease or at High Risk for Cardiovascular Disease, on Stable Lipid-Lowering Therapy Requiring Additional Low-Density Lipoprotein Cholesterol Reduction
    Disease: Version SOC Term Classification Code Term Level
    20.1 100000004849 10007648 Cardiovascular disease, unspecified LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) NO (Completed) ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2020-004392-40 Sponsor Protocol Number: LIB003-005 Start Date*: 2021-12-21
    Sponsor Name:LIB Therapeutics, LLC
    Full Title: Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study to Evaluate the Long-Term Efficacy and Safety of LIB003 in Patients With Cardiovascular Disease on Stable Lipid-Lowering Therapy Requirin...
    Medical condition: Patients With Cardiovascular Disease on Stable Lipid-Lowering Therapy Requiring Additional Low-Density Lipoprotein Cholesterol Reduction
    Disease: Version SOC Term Classification Code Term Level
    20.1 100000004849 10007648 Cardiovascular disease, unspecified LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) NO (Completed) ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2011-001528-39 Sponsor Protocol Number: 20090158 Start Date*: 2011-07-13
    Sponsor Name:Amgen Inc
    Full Title: "A Double-blind, Radomized, Placebo-comtrolled, Multicenter Study to Evaluate Tolerability and Efficacy of AMG 145 on LDL-C in Subjects with Heterozygous Familial Hypercholesterolemia"
    Medical condition: Heterozygous familial hypercholesterolemia
    Disease: Version SOC Term Classification Code Term Level
    13.1 10010331 - Congenital, familial and genetic disorders 10057099 Heterozygous familial hypercholesterolaemia LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Completed) GB (Completed) DE (Completed) SE (Completed)
    Trial results: View results
    EudraCT Number: 2016-003486-26 Sponsor Protocol Number: 1002-047 Start Date*: 2017-05-24
    Sponsor Name:Esperion Therapeutics Inc.,
    Full Title: A Long-term, Randomized, Double-blind, Placebo-controlled, Multicenter Study to Evaluate the Efficacy of Bempedoic Acid (ETC-1002) in Patients with Hyperlipidemia at High Cardiovascular Risk Not Ad...
    Medical condition: Patients with Hyperlipidemia at High Cardiovascular Risk Not Adequately Controlled by Their Lipid-Modifying Therapy
    Disease: Version SOC Term Classification Code Term Level
    20.1 10007541 - Cardiac disorders 10007648 Cardiovascular disease, unspecified LLT
    20.0 10007541 - Cardiac disorders 10007649 Cardiovascular disorder PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) GB (Completed)
    Trial results: View results
    EudraCT Number: 2021-002871-20 Sponsor Protocol Number: LIB003-012 Start Date*: 2022-04-21
    Sponsor Name:LIB Therapeutics, LLC
    Full Title: Randomized, Open Label, Phase 3 Study to Evaluate the Efficacy and Safety of Lerodalcibep (LIB003) compared to Inclisiran in Patients With Cardiovascular Disease, or at High Risk for Cardiovascula...
    Medical condition: Patients with atherosclerotic cardiovascular (CV) disease (ASCVD) or high risk of ASCVD who need additional LDL-C reduction
    Disease: Version SOC Term Classification Code Term Level
    20.1 100000004849 10007648 Cardiovascular disease, unspecified LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) FR (Completed) NO (Completed) ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2021-005092-39 Sponsor Protocol Number: TA-8995-304 Start Date*: 2022-08-25
    Sponsor Name:NewAmsterdam Pharma BV
    Full Title: Obicetrapib and Cardiovascular Outcomes: A Placebo-Controlled, Double-Blind, Randomized Phase 3 Study to Evaluate the Effect of 10 mg Obicetrapib in Participants With Atherosclerotic Cardiovascular...
    Medical condition: atherosclerotic cardiovascular disease (ASCVD)
    Disease: Version SOC Term Classification Code Term Level
    26.0 100000004866 10051615 Atherosclerotic cardiovascular disease LLT
    20.0 100000004866 10076622 Atherosclerotic plaque LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Trial now transitioned) IT (Trial now transitioned) SK (Trial now transitioned) NL (Trial now transitioned) HU (Trial now transitioned) BG (Trial now transitioned) DK (Trial now transitioned) CZ (Trial now transitioned) FI (Trial now transitioned) LV (Trial now transitioned) ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2013-002984-24 Sponsor Protocol Number: PHS-Px-104-II-01 Start Date*: 2013-10-07
    Sponsor Name:Phenex Pharmaceuticals AG
    Full Title: A Safety Pilot Study of Px-104 in non alcoholic fatty liver disease (NAFLD) patients
    Medical condition: Non-alcoholic fatty liver disease (NAFLD)
    Disease: Version SOC Term Classification Code Term Level
    16.1 10019805 - Hepatobiliary disorders 10024670 Liver disorder PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: AT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2015-004136-36 Sponsor Protocol Number: 1002-040 Start Date*: 2016-06-14
    Sponsor Name:Esperion Therapeutics, Inc.
    Full Title: A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTI-CENTER LONG-TERM SAFETY AND TOLERABILITY STUDY OF ETC-1002 IN PATIENTS WITH HYPERLIPIDEMIA AT HIGH CARDIOVASCULAR RISK WHO ARE NOT ADEQUATELY C...
    Medical condition: Treatment of high cardiovascular risk patients (heterozygous familial hypercholesterolemia [HeFH] and atherosclerotic cardiovascular diseases [ASCVD]) with hyperlipidemia
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000019513 10020604 Hypercholesterolemia LLT
    20.0 100000019521 10020667 Hyperlipidemia LLT
    20.0 100000022953 10051615 Atherosclerotic cardiovascular disease LLT
    20.0 100000012386 10057079 Heterozygous familial hypercholesterolemia LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Completed) GB (Completed) DE (Completed) PL (Completed)
    Trial results: View results
    EudraCT Number: 2012-004208-37 Sponsor Protocol Number: 20120153 Start Date*: 2013-04-23
    Sponsor Name:Amgen Inc
    Full Title: A Randomized, Multi-Center, Placebo-Controlled, Parallel Group Study to Determine the Effects of AMG-145 Treatment on Atherosclerotic Disease Burden As Measured By Intravascular Ultrasound in Patie...
    Medical condition: Coronary Artery Disease
    Disease: Version SOC Term Classification Code Term Level
    14.1 100000004849 10011079 Coronary artery disease NOS LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed) NL (Completed) BE (Completed) SE (Completed) CZ (Completed) HU (Completed) ES (Completed) DE (Completed) GR (Completed) FI (Prematurely Ended) NO (Completed) IE (Completed) DK (Prematurely Ended) IS (Completed)
    Trial results: View results
    EudraCT Number: 2004-000354-22 Sponsor Protocol Number: A3841029 Start Date*: 2004-12-06
    Sponsor Name:Pfizer Healthcare Ireland
    Full Title: An International, Multicentre, Open Label Study To Assess The Effectiveness Of Amlodipine –Atorvastatin Combination In Subjects With Hypertension and Dyslipidaemia. (The JEWEL II Study)
    Medical condition: Concurrent hypertension (ICD code 80011/MedDRA: coded under preferred term "vascular system order", code 10020772) and dyslipidaemia (ICD code 89212/MedDRA: coded under preferred term "metabolism a...
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IE (Completed) ES (Completed) AT (Completed) HU (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2008-006271-70 Sponsor Protocol Number: P05522 Start Date*: 2009-03-03
    Sponsor Name:Schering-Plough Research Institute, A Division of Schering Corporation,
    Full Title: A Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Efficacy and Safety Study of Ezetimibe Monotherapy in Children (Ages 6 to 10 Years) With Primary Hypercholesterolemia (Heterozygous Fa...
    Medical condition: -Primary Hypercholesterolemia (Heterozygous Familial [HeFH]) -Primary Hypercholesterolemia (Nonfamilial)
    Disease: Version SOC Term Classification Code Term Level
    9.1 10057079 Heterozygous familial hypercholesterolemia LLT
    9.1 10020604 Hypercholesterolemia LLT
    Population Age: Children, Under 18 Gender: Male, Female
    Trial protocol: NL (Completed) FR (Completed) IT (Completed) GR (Completed) Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2019-002278-30 Sponsor Protocol Number: APH-19 Start Date*: 2020-08-12
    Sponsor Name:Amryt Pharmaceuticals DAC
    Full Title: Phase III, single-arm, open-label, international, multi-centre study to evaluate the efficacy and safety of lomitapide in paediatric patients with Homozygous Familial Hypercholesterolaemia (HoFH) o...
    Medical condition: Homozygous familial hypercholesterolaemia (HoFH). A rare and life-threatening inherited disorder of lipid metabolism with an estimated prevalence of 1 per 160,000 to 300,000 in the European populat...
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004850 10057100 Homozygous familial hypercholesterolaemia LLT
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: DE (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2016-002240-17 Sponsor Protocol Number: ATR-101-301 Start Date*: 2017-05-16
    Sponsor Name:Millendo Therapeutics, Inc.
    Full Title: A Phase 2 Randomized, Double-Blind, Placebo-Controlled Study of ATR-101 for the Treatment of Cushing’s Syndrome
    Medical condition: endogenous Cushing’s syndrome
    Disease: Version SOC Term Classification Code Term Level
    20.0 10014698 - Endocrine disorders 10014698 Endocrine disorders SOC
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2006-001715-30 Sponsor Protocol Number: RIMON_R_00962 Start Date*: 2006-10-23
    Sponsor Name:sanofi aventis Groupe
    Full Title: A European randomized, parallel group, two-arm placebo-controlled, double-blind multicenter study of Rimonabant 20mg once daily in the treatment of abdominally obese patients with dyslipidemia with...
    Medical condition: abdominally obese patients with dyslipidemia with or without other comorbidities
    Disease: Version SOC Term Classification Code Term Level
    8.1 10059179 Abdominal obesity LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: PT (Prematurely Ended) CZ (Completed) SI (Completed) NL (Completed) SE (Prematurely Ended) FI (Prematurely Ended) DE (Prematurely Ended) SK (Completed) HU (Completed) GR (Completed) IT (Prematurely Ended) GB (Completed)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  3  Next»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Wed Jun 04 18:48:45 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA